Neoplasms, Basal Cell: Clinical Trials

26 trials for Neoplasms, Basal Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 unknown, 2 recruiting, 2 terminated. 26 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 326Completed 16, Unknown 3, Recruiting 2, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1
Phase 23Completed 2, Withdrawn 1

Follow Neoplasms, Basal Cell: new trials by email Literature Review of Neoplasms, Basal Cell trials Research Report on Neoplasms, Basal Cell

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Basal Cell Carcinoma Chemoprevention Trial
5% Imiquimod cream, Placebo Vehicle Control Cream - Basal Cell Carcinoma
Phase 3RecruitingVA Office of Research and Development16302026-10-062026-11-02
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel - Advanced Basal Cell Carcinoma (BCC), Inoperable Disease
Phase 3Enrolling by invitationDaryoush Hamidi Alamdari, PhD202025-10-212026-01-06
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome
Phase 3CompletedSol-Gel Technologies, Ltd.1132024-03-172026-09-18
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Nicotinamide, Placebo - Non-melanoma Skin Cancer, Carcinoma, Squamous Cell
Phase 3RecruitingWomen's College Hospital3962023-08-282026-10-13
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma
5-Fluorouracil, SURGERY - Basal Cell Carcinoma, BCC
Phase 3UnknownUniversity of Aleppo402023-05-252024-01-02
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Reduced dose intensity of IO - Lung Cancer Metastatic, Renal Cell Carcinoma
Phase 3Active not recruitingUNICANCER6462022-03-082026-07-17
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Patidegib Topical Gel, 2% - Basal Cell Nevus Syndrome
Phase 3TerminatedSol-Gel Technologies, Ltd.1082020-06-032024-09-24
Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study
Calcium chloride - Basal Cell Carcinoma
Phase 3UnknownBispebjerg Hospital252020-01-082021-09-16
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Basal Cell Nevus Syndrome
Phase 3CompletedSol-Gel Technologies, Ltd.1742019-02-192024-07-03
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
Sinecatechins 10%, Placebo - Carcinoma, Basal Cell
Phase 2 / Phase 3CompletedMaastricht University Medical Center422014-11-012016-05-18
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
BF-200 ALA, methyl-aminolevulinate - Basal Cell Carcinoma (BCC)
Phase 3CompletedBiofrontera Bioscience GmbH2812014-01-282022-11-03
Fractional CO2 Laser Assisted Photodynamic Therapy
Conventional photodynamic therapy, Fractional CO2 laser assisted PDT - Actinic Keratosis, Basal Cell Carcinoma
Phase 2 / Phase 3CompletedBispebjerg Hospital472010-10-012015-07-30
Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma
Immunocryosurgery, Cryoimmunotherapy - Basal Cell Carcinoma
Phase 3CompletedUniversity of Ioannina142009-02-012011-09-02
Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control
Permanent Section Control, Frozen Section Control - Basal Cell Carcinoma
Phase 3UnknownQueen's University2902008-08-012011-07-12
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Imiquimod 5% cream - Basal Cell Carcinoma
Phase 3CompletedGraceway Pharmaceuticals, LLC632004-01-012010-07-16
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Photodynamic therapy with Metvix 160 mg/g cream - Actinic Keratosis, Warts
Phase 3CompletedGalderma R&D822003-07-252025-04-18
Aldara for the Treatment of Large and/or Multiple sBCC
Imiquimod - Carcinoma, Basal Cell
Phase 3CompletedMEDA Pharma GmbH & Co. KG1112003-05-012022-02-22
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
imiquimod, conventional surgery - Non-melanomatous Skin Cancer
Phase 3CompletedQueen's Medical Center5002002-10-012013-09-17
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
imiquimod - Basal Cell Carcinoma
Phase 3CompletedMEDA Pharma GmbH & Co. KG1602001-02-012022-02-07
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Photodynamic Therapy (PDT), Metvix cream, Placebo Cream - Basal Cell Carcinoma
Phase 3CompletedGalderma R&D652000-12-012024-08-05

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Carcinoma, Basal Cell (25)  ·  Basal Cell Nevus Syndrome (5)  ·  Carcinoma, Squamous Cell (4)  ·  Keratosis, Actinic (3)  ·  Basal cell carcinoma, multiple (1)  ·  Bowen's Disease (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Head and Neck Neoplasms (1)  ·  Melanoma (1)  ·  Patient Compliance (1)

Broader conditions

Carcinoma (26)  ·  Neoplasms (26)  ·  Neoplasms by Histologic Type (26)  ·  Neoplasms, Glandular and Epithelial (26)  ·  Abnormalities, Multiple (5)  ·  Bone Cysts (5)  ·  Bone Diseases (5)  ·  Bone Diseases, Developmental (5)  ·  Congenital Abnormalities (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Cysts (5)  ·  Genetic Diseases, Inborn (5)  ·  Jaw Cysts (5)  ·  Jaw Diseases (5)

Interventions

Imiquimod (4)  ·  methyl 5-aminolevulinate (3)  ·  Photochemotherapy (2)  ·  1-phenyl-3,3-dimethyltriazene (1)  ·  Aminolevulinic Acid (1)  ·  BF-200 ALA (1)  ·  Calcium Chloride (1)  ·  Eflornithine (1)  ·  Electroporation (1)  ·  Fluorouracil (1)  ·  IPI-926 (1)  ·  Niacinamide (1)  ·  Surgical Procedures, Operative (1)  ·  Tretinoin (1)  ·  green tea extract polyphenone E (1)

Sponsors

Galderma R&D (4)  ·  Sol-Gel Technologies, Ltd. (3)  ·  Bispebjerg Hospital (2)  ·  MEDA Pharma GmbH & Co. KG (2)  ·  Biofrontera Bioscience GmbH (1)  ·  Daryoush Hamidi Alamdari, PhD (1)  ·  Graceway Pharmaceuticals, LLC (1)  ·  Maastricht University Medical Center (1)  ·  Novartis Pharmaceuticals (1)  ·  QLT Inc. (1)  ·  Queen's Medical Center (1)  ·  Queen's University (1)  ·  UNICANCER (1)  ·  US Department of Veterans Affairs (1)  ·  University of Aleppo (1)

Countries

Germany (7)  ·  United States (7)  ·  United Kingdom (6)  ·  Denmark (5)  ·  France (5)  ·  Canada (4)  ·  Italy (4)  ·  Netherlands (4)  ·  Spain (4)  ·  Belgium (3)  ·  Australia (2)  ·  Greece (2)  ·  Czechia (1)  ·  Finland (1)  ·  Iran (1)

Top investigators

Martin A. Weinstock, MD (2)  ·  Ahmad Yamen Arnaout, M.D. (1)  ·  An-Wen Chan (1)  ·  Ann-Marie Wennberg, MD, PhD (1)  ·  Carl Vinciullo, MD (1)  ·  Colin Morton, Dr. (1)  ·  Herma Neyndorff (1)  ·  Ioannis D Bassukas, Professor (1)  ·  Mara Ozolins, MS (1)  ·  Nicole WJ Kelleners-Smeets, MD, PhD (1)  ·  Noura Abdulrahman, M.D. (1)  ·  Paul P. Carbone, MD (1)

Results publications

PMID 19124815, PMID 19153339, PMID 20409337, PMID 24332516, PMID 27932240, PMID 29432644, PMID 37131154

NIH funding

2023 (1), U01CA077158 (1)